Cargando…
What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis
BACKGROUND: PCSK9 rs505151 and rs11591147 polymorphisms are identified as gain- and loss-of-function mutations, respectively. The effects of these polymorphisms on serum lipid levels and cardiovascular risk remain to be elucidated. METHODS: In this meta-analysis, we explored the association of PCSK9...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469167/ https://www.ncbi.nlm.nih.gov/pubmed/28606094 http://dx.doi.org/10.1186/s12944-017-0506-6 |
_version_ | 1783243538266324992 |
---|---|
author | Qiu, Chengfeng Zeng, Pingyu Li, Xiaohui Zhang, Zhen Pan, Bingjie Peng, Zhou Y. F. Li, Yapei Ma, Yeshuo Leng, Yiping Chen, Ruifang |
author_facet | Qiu, Chengfeng Zeng, Pingyu Li, Xiaohui Zhang, Zhen Pan, Bingjie Peng, Zhou Y. F. Li, Yapei Ma, Yeshuo Leng, Yiping Chen, Ruifang |
author_sort | Qiu, Chengfeng |
collection | PubMed |
description | BACKGROUND: PCSK9 rs505151 and rs11591147 polymorphisms are identified as gain- and loss-of-function mutations, respectively. The effects of these polymorphisms on serum lipid levels and cardiovascular risk remain to be elucidated. METHODS: In this meta-analysis, we explored the association of PCSK9 rs505151 and rs11591147 polymorphisms with serum lipid levels and cardiovascular risk by calculating the standardized mean difference (SMD) and odds ratios (OR) with 95% confidence intervals (CI). RESULTS: Pooled results analyzed under a dominant genetic model indicated that the PCSK9 rs505151 G allele was related to higher levels of triglycerides (SMD: 0.14, 95% CI: 0.02 to 0.26, P = 0.021, I(2) = 0) and low-density lipoproteins cholesterol (LDL-C) (SMD: 0.17, 95% CI: 0.00 to 0.35, P = 0.046, I(2) = 75.9%) and increased cardiovascular risk (OR: 1.50, 95% CI: 1.19 to 1.89, P = 0.0006, I(2) = 48%). The rs11591147 T allele was significantly associated with lower levels of total cholesterol (TC) and LDL-C (TC, SMD: -0.45, 95% CI: -0.57 to −0.32, P = 0.000, I(2) = 0; LDL-C, SMD: -0.44, 95% CI: -0.55 to −0.33, P = 0.000, I(2) = 0) and decreased cardiovascular risk (OR: 0.77, 95% CI: 0.60 to 0.98, P = 0.031, I(2) = 59.9) in Caucasians. CONCLUSIONS: This study indicates that the variant G allele of PCSK9 rs505151 confers increased triglyceride (TG) and LDL-C levels, as well as increased cardiovascular risk. Conversely, the variant T allele of rs11591147 protects carriers from cardiovascular disease susceptibility and lower TC and LDL-C levels in Caucasians. These findings provide useful information for researchers interested in the fields of PCSK9 genetics and cardiovascular risk prediction not only for designing future studies, but also for clinical and public health applications. |
format | Online Article Text |
id | pubmed-5469167 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54691672017-06-14 What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis Qiu, Chengfeng Zeng, Pingyu Li, Xiaohui Zhang, Zhen Pan, Bingjie Peng, Zhou Y. F. Li, Yapei Ma, Yeshuo Leng, Yiping Chen, Ruifang Lipids Health Dis Research BACKGROUND: PCSK9 rs505151 and rs11591147 polymorphisms are identified as gain- and loss-of-function mutations, respectively. The effects of these polymorphisms on serum lipid levels and cardiovascular risk remain to be elucidated. METHODS: In this meta-analysis, we explored the association of PCSK9 rs505151 and rs11591147 polymorphisms with serum lipid levels and cardiovascular risk by calculating the standardized mean difference (SMD) and odds ratios (OR) with 95% confidence intervals (CI). RESULTS: Pooled results analyzed under a dominant genetic model indicated that the PCSK9 rs505151 G allele was related to higher levels of triglycerides (SMD: 0.14, 95% CI: 0.02 to 0.26, P = 0.021, I(2) = 0) and low-density lipoproteins cholesterol (LDL-C) (SMD: 0.17, 95% CI: 0.00 to 0.35, P = 0.046, I(2) = 75.9%) and increased cardiovascular risk (OR: 1.50, 95% CI: 1.19 to 1.89, P = 0.0006, I(2) = 48%). The rs11591147 T allele was significantly associated with lower levels of total cholesterol (TC) and LDL-C (TC, SMD: -0.45, 95% CI: -0.57 to −0.32, P = 0.000, I(2) = 0; LDL-C, SMD: -0.44, 95% CI: -0.55 to −0.33, P = 0.000, I(2) = 0) and decreased cardiovascular risk (OR: 0.77, 95% CI: 0.60 to 0.98, P = 0.031, I(2) = 59.9) in Caucasians. CONCLUSIONS: This study indicates that the variant G allele of PCSK9 rs505151 confers increased triglyceride (TG) and LDL-C levels, as well as increased cardiovascular risk. Conversely, the variant T allele of rs11591147 protects carriers from cardiovascular disease susceptibility and lower TC and LDL-C levels in Caucasians. These findings provide useful information for researchers interested in the fields of PCSK9 genetics and cardiovascular risk prediction not only for designing future studies, but also for clinical and public health applications. BioMed Central 2017-06-12 /pmc/articles/PMC5469167/ /pubmed/28606094 http://dx.doi.org/10.1186/s12944-017-0506-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Qiu, Chengfeng Zeng, Pingyu Li, Xiaohui Zhang, Zhen Pan, Bingjie Peng, Zhou Y. F. Li, Yapei Ma, Yeshuo Leng, Yiping Chen, Ruifang What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis |
title | What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis |
title_full | What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis |
title_fullStr | What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis |
title_full_unstemmed | What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis |
title_short | What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis |
title_sort | what is the impact of pcsk9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5469167/ https://www.ncbi.nlm.nih.gov/pubmed/28606094 http://dx.doi.org/10.1186/s12944-017-0506-6 |
work_keys_str_mv | AT qiuchengfeng whatistheimpactofpcsk9rs505151andrs11591147polymorphismsonserumlipidslevelandcardiovascularriskametaanalysis AT zengpingyu whatistheimpactofpcsk9rs505151andrs11591147polymorphismsonserumlipidslevelandcardiovascularriskametaanalysis AT lixiaohui whatistheimpactofpcsk9rs505151andrs11591147polymorphismsonserumlipidslevelandcardiovascularriskametaanalysis AT zhangzhen whatistheimpactofpcsk9rs505151andrs11591147polymorphismsonserumlipidslevelandcardiovascularriskametaanalysis AT panbingjie whatistheimpactofpcsk9rs505151andrs11591147polymorphismsonserumlipidslevelandcardiovascularriskametaanalysis AT pengzhouyf whatistheimpactofpcsk9rs505151andrs11591147polymorphismsonserumlipidslevelandcardiovascularriskametaanalysis AT liyapei whatistheimpactofpcsk9rs505151andrs11591147polymorphismsonserumlipidslevelandcardiovascularriskametaanalysis AT mayeshuo whatistheimpactofpcsk9rs505151andrs11591147polymorphismsonserumlipidslevelandcardiovascularriskametaanalysis AT lengyiping whatistheimpactofpcsk9rs505151andrs11591147polymorphismsonserumlipidslevelandcardiovascularriskametaanalysis AT chenruifang whatistheimpactofpcsk9rs505151andrs11591147polymorphismsonserumlipidslevelandcardiovascularriskametaanalysis |